At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CERO CERo Therapeutics Holdings, Inc.
Post-Mkt 03-04 16:07:45 EST Delay
盘后0.0350
-0.0030-7.89%
16:07 EST
Cero Therapeutics Announces Biotech Industry Veteran Eric Francois to Join Its Board of Directors
THOMSON REUTERS  ·  02-17
Cero Therapeutics Announces Biotech Industry Veteran Eric Francois to Join Its Board of Directors
Cero Therapeutics to present data from Phase 2 trial of CER-1236
TIPRANKS  ·  02-04
Cero Therapeutics to present data from Phase 2 trial of CER-1236
BRIEF-Cero Therapeutics Hearing Review Council Issued Decision
Reuters  ·  02-04
BRIEF-Cero Therapeutics Hearing Review Council Issued Decision
Cero Therapeutics: Hearing Review Council Issued Decision Affirming Nasdaq Hearing Panel's Decision to Delist Company’s Securities From Nasdaq
THOMSON REUTERS  ·  02-04
Cero Therapeutics: Hearing Review Council Issued Decision Affirming Nasdaq Hearing Panel's Decision to Delist Company’s Securities From Nasdaq
Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236
Reuters  ·  01-07
Cero Therapeutics Reports Positive Safety Data in Phase 1 AML Trial of CER-1236
Cero Therapeutics Holdings Inc - No Adverse Events Reported in First Cohort of Certaint-1 Trial
THOMSON REUTERS  ·  01-07
Cero Therapeutics Holdings Inc - No Adverse Events Reported in First Cohort of Certaint-1 Trial
Cero Therapeutics Provides Clinical Update on Phase 1 Trial of Cer-1236 in Aml (Certaint-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient With Myelodysplastic Syndrome/Aml
THOMSON REUTERS  ·  01-07
Cero Therapeutics Provides Clinical Update on Phase 1 Trial of Cer-1236 in Aml (Certaint-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient With Myelodysplastic Syndrome/Aml
Cero Therapeutics Holdings Inc. held special shareholder meeting
Reuters  ·  2025-12-20
Cero Therapeutics Holdings Inc. held special shareholder meeting
BRIEF-Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Reuters  ·  2025-12-17
BRIEF-Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Cero Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of Cer-1236 in Aml (Certaint-1)
THOMSON REUTERS  ·  2025-12-17
Cero Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of Cer-1236 in Aml (Certaint-1)
Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia
Reuters  ·  2025-12-17
Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia
BRIEF-Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List
Reuters  ·  2025-12-02
BRIEF-Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List
Cero Therapeutics Announces $14.6 Million Private Stock Sale to Institutional Investor
Reuters  ·  2025-12-02
Cero Therapeutics Announces $14.6 Million Private Stock Sale to Institutional Investor
Cero Therapeutics Holdings Inc - Continues to Evaluate Additional Options for up-List
THOMSON REUTERS  ·  2025-12-02
Cero Therapeutics Holdings Inc - Continues to Evaluate Additional Options for up-List
CERo Therapeutics Cut to Hold From Buy by D. Boral Capital
Dow Jones  ·  2025-11-19
CERo Therapeutics Cut to Hold From Buy by D. Boral Capital
Cero Therapeutics Holdings Inc. Announces Date for 2025 Special Meeting of Stockholders
Reuters  ·  2025-11-17
Cero Therapeutics Holdings Inc. Announces Date for 2025 Special Meeting of Stockholders
CERo Therapeutics Advances Phase 1 AML Trial with Higher Dosing of CER-1236
Reuters  ·  2025-11-05
CERo Therapeutics Advances Phase 1 AML Trial with Higher Dosing of CER-1236
Cero Therapeutics Presents Promising Phase 1 Data for Lead Immunotherapy CER-1236 in AML
Reuters  ·  2025-11-04
Cero Therapeutics Presents Promising Phase 1 Data for Lead Immunotherapy CER-1236 in AML
Cero Therapeutics announces listing on OTC Markets
TIPRANKS  ·  2025-11-03
Cero Therapeutics announces listing on OTC Markets
Cero Therapeutics discloses Nasdaq Panel listing determination
TIPRANKS  ·  2025-10-30
Cero Therapeutics discloses Nasdaq Panel listing determination

Introduction

Company Name.
CERo Therapeutics Holdings, Inc.
Affiliated Markets:
OTCQB
Listing Date:
--
Main Business:
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.
Issue price:
--